Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serine/threonine kinase AMP-activated protein kinase (AMPK) is a drug target for the treatment of obesity and type 2 diabetes (T2D).
|
31836952 |
2019 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
EPS improved insulin signal transduction in myotubes from lean but not severely obese subjects and increased AMP accumulation and AMPK Thr<sup>172</sup> phosphorylation, but to a lesser degree in myotubes from the severely obese.
|
30414190 |
2019 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Platycodin D, a novel activator of AMP-activated protein kinase, attenuates obesity in db/db mice via regulation of adipogenesis and thermogenesis.
|
30599906 |
2019 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BH has been revealed to decrease serum cholesterol and triacylglycerol (triglyceride or TG) levels through the activation of AMP‑activated protein kinase (AMPK), thus it is expected to be a health functional food and pharmaceutical agent for the prevention of non‑alcoholic liver damage, in addition to effects as a suppressor of hyperlipidemia and as an anti‑obesity agent.
|
30221679 |
2018 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Black tea affects obesity by reducing nutrient intake and activating AMP-activated protein kinase in mice.
|
29923153 |
2018 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The AMP-activated protein kinase (AMPK) is a central regulator of multiple metabolic pathways and may have therapeutic importance for treating obesity, insulin resistance, type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease (CVD).
|
28647324 |
2017 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Obesity in WT mice fed a HFD associated with elevated serum IL-6 levels, fatty liver, upregulation of carnitine palmitoyltransferase 1 (CPT1) and signal transducer and activator of transcription-3 (STAT3), increased AMP kinase phosphorylation (p-AMPK), and downregulation of the hepatic lipogenic enzymes fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1).
|
26035386 |
2015 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women.
|
19509226 |
2009 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclic AMP effects are mainly mediated by protein kinase A (PKA), whose R2B regulatory isoform is the most expressed in mouse adipose tissue, where it protects against diet-induced obesity and fatty liver development.
|
19095761 |
2009 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) is involved in cellular stress responses linked to obesity and type 2 diabetes.
|
19652946 |
2009 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The factors contributing to defects in fatty acid metabolism are not understood but new data demonstrates that increased TNFalpha in obesity increases protein phosphatase 2C (PP2C), which in turn suppresses the activity of AMP-activated protein kinase (AMPK), a critical regulator of energy metabolism.
|
17438370 |
2007 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase.
|
16224049 |
2005 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Key cellular mediators (namely SREBP-1c and 2, AMP activated protein kinase, cholesterol content) of the regulation of lipogenic gene expression by glucose and/or insulin were identified and constitute new putative targets in the development of plurimetabolic syndrome associated with obesity.
|
11894744 |
2001 |